ScreenerHero
XSPRAYXspray Pharma AB (publ)
STO · SE · Healthcare · Biotechnology · xspraypharma.com
10.46SEK+0.58%Mkt Cap: 47.44M $P/E: —

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap47.44M $
Enterprise Value44.05M $
Revenue (TTM)235.88K $
Gross Profit235.88K $
Net Income (TTM)-16.40M $
Revenue/Share0.0056 USD
Last Price10.46 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.57
PEG—
EV/EBITDA-3.18
EV/Revenue186.75
P/S200.74
P/B0.77
EPS (TTM)-3.81
EPS (Forward)-1.59
52W Range
10.200% of range64.10
52W High64.10 SEK
52W Low10.20 SEK
Profitability
Gross Margin100.00%
Oper. Margin-464.62%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.35%
ROA-22.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.48M $
CapEx (TTM)2.79M $
FCF Margin-4963.16%
FCF Yield-24.68%
Net Debt-3.12M $
Net Debt/EBITDA0.22
Balance Sheet
Debt/Equity0.25
Current Ratio1.39
Quick Ratio1.19
Book Value/Sh13.64 SEK
Cash/Share3.794 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)60.00 SEK
Upside (mean)+473.6%
Target Range60.00 SEK – 60.00 SEK
# Analysts1
Ownership
Shares Out.47.42M
Float33.92M
Insiders21.68%
Institutions40.89%
Technical
SMA 5015.17 (-31.1%)
SMA 20023.90 (-56.2%)
Beta-0.03
S&P 52W Chg18.16%
Avg Vol (30d)149.39K
Avg Vol (10d)293.95K
Technical Indicators
RSI (14)21.2
MACD-1.1643
MACD Signal-0.7272
MACD Hist.-0.4371
BB Upper18.48 SEK
BB Middle14.76 SEK
BB Lower11.04 SEK
BB Width50.38%
ATR (14)1.154 SEK
Vol Ratio (20d)2.70x